The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam.

Abstract

OBJECTIVE:

The objective of this study was to evaluate whether the outcomes of carbapenem-resistant Acinetobacter infections treated with ampicillin/sulbactam were associated with the in vitro susceptibility profiles.

METHODS:

Twenty-two infections were treated with ampicillin/sulbactam. The median treatment duration was 14 days (range: 3-19 days), and the median daily dose was 9 g (range: 1.5-12 g). The median time between Acinetobacter isolation and treatment was 4 days (range: 0-11 days).

RESULTS:

The sulbactam minimal inhibitory concentration (MIC) ranged from 2.0 to 32.0 mg/L, and the MIC was not associated with patient outcome, as 4 of 5 (80%) patients with a resistant infection (MIC≥16), 5 of 10 (50%) patients with intermediate isolates (MIC of 8) and only 1 of 7 (14%) patients with susceptible isolates (MIC ≤4) survived hospitalization.

CONCLUSION:

These findings highlight the need to improve the correlation between in vitro susceptibility tests and clinical outcome.

• Authors: Maura S de Oliveira, Silvia Figueiredo Costa, Ewerton de Pedri, Inneke van der Heijden, Anna Sara S Levin
• Journal: Clinics (Sao Paulo, Brazil) (Clinics (Sao Paulo)) Vol. 68 Issue 4 Pg. 569-73 (Apr 2013) ISSN: 1980-5322 [Electronic] United States
• PMID: 23778333 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Ampicillin
• Sulbactam

Topics

• Acinetobacter (drug effects)
• Acinetobacter Infections (drug therapy, mortality)
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Ampicillin (administration & dosage)
• Anti-Bacterial Agents (administration & dosage)
• Carbapenems (administration & dosage)
• Child
• Female
• Hospital Mortality
• Humans
• Male
• Microbial Sensitivity Tests
• Middle Aged
• Multivariate Analysis
• Sulbactam (administration & dosage)
• Treatment Outcome
• Young Adult
• beta-Lactam Resistance